Your browser doesn't support javascript.
loading
Successful treatment of Chronic Myelogenic Leukemia (CML) with imatinib after renal transplantation.
Eishei Oskuei, Ali; Makhdoomi, Khadijeh; Abkhiz, Saeed; Vossoghian, Sara; Farrokhpour, Mohsen.
Afiliação
  • Eishei Oskuei A; Associate Professor of Hematology and Oncology, Uromia University of Medical Sciences, Iran. Makhdoomikhadijeh@yahoo.com.
  • Makhdoomi K; Associate Professor of Nephrology, Nephrology and Kidney Transplant Research Center, Uromia, Iran.
  • Abkhiz S; Assistant professor of Nephrology , Uromia University of Medical Sciences, Uromia, Iran.
  • Vossoghian S; Resident of Internal Medicine, Uromia University of Medical Sciences, Iran.
  • Farrokhpour M; Resident of Internal Medicine, Uromia University of Medical Sciences, Iran.
Arch Iran Med ; 17(5): 388-90, 2014 May.
Article em En | MEDLINE | ID: mdl-24784871
ABSTRACT
Chronic Myelogenic Leukemia (CML) is a rare malignant disorder after solid organ transplantation, especially in renal transplant recipients. Imatinib Mesylate is currently approved as first line treatment of CML. Most reports on CML are from kidney recipients who received azathioprine  in combination with cyclosporine and prednisolone as immunosuppressive therapy. We report a case with CML who was treated with Mycophenolate Mofetil.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piperazinas / Pirimidinas / Benzamidas / Leucemia Mielogênica Crônica BCR-ABL Positiva / Transplante de Rim / Antineoplásicos Idioma: En Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Irã
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piperazinas / Pirimidinas / Benzamidas / Leucemia Mielogênica Crônica BCR-ABL Positiva / Transplante de Rim / Antineoplásicos Idioma: En Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Irã